Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE vs cTACE for primary liver cancer
ChiCTR2100050928Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of drug-eluting bead transarterial chemoembolization and conventional transarterial chemoembolization in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Progression-free survival and Serious adverse events. Started Sep 2021; status: recruiting.
02
Drugs
drug-eluting bead transarterial chemoembolizationconventional transarterial chemoembolization
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100050928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050928.